Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
- DOI
- 10.1136/esmoopen-2020-000979
- Published
- 2020 Nov
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/esmoopen-2020-000979,
title = {Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.},
author = {Lambertini M and Agbor-Tarh D and Metzger-Filho O and Ponde NF and Poggio F and Hilbers FS and Korde LA and Chumsri S and Werner O and Del Mastro L and Caparica R and Moebus V and Moreno-Aspitia A and Piccart MJ and de Azambuja E},
year = {2020},
journal = {ESMO open},
doi = {10.1136/esmoopen-2020-000979},
url = {https://doi.org/10.1136/esmoopen-2020-000979}
}RIS
TY - JOUR TI - Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. AU - Lambertini M AU - Agbor-Tarh D AU - Metzger-Filho O AU - Ponde NF AU - Poggio F AU - Hilbers FS AU - Korde LA AU - Chumsri S AU - Werner O AU - Del Mastro L AU - Caparica R AU - Moebus V AU - Moreno-Aspitia A AU - Piccart MJ AU - de Azambuja E PY - 2020 JO - ESMO open DO - 10.1136/esmoopen-2020-000979 UR - https://doi.org/10.1136/esmoopen-2020-000979 ER -
APA
M, L., D, A., O, M., NF, P., F, P., FS, H., LA, K., S, C., O, W., L, D. M., R, C., V, M., A, M., MJ, P., & E, D. A. (2020). Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.. ESMO open. https://doi.org/10.1136/esmoopen-2020-000979
Source records
- pubmed · retrieved 2026-09-25T10:31:18.121Z
- europe-pmc · retrieved 2026-09-25T10:31:18.138Z
- doaj · retrieved 2026-09-25T10:31:18.127Z